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Hereditary leukonychia (porcelain nails or white nails) is a rare nail disorder with an unknown genetic basis. To identify variants in
a gene underlying this phenotype, we identified four families of Pakistani origin showing features of hereditary leukonychia. All 20 nails
of each affected individual were chalky and white in appearance, consistent with total leukonychia, with no other cutaneous, appenda-
geal, or systemic findings. By using Affymetrix 10K chip, we established linkage to chromosome 3p21.3-p22 with a LOD score (Z) of 5.1.
We identified pathogenic mutations in PLCD1 in all four families, which encodes phosphoinositide-specific phospholipase C delta 1
subunit, a key enzyme in phosphoinositide metabolism. We then identified localization of PLCD1 in the nail matrix. It was recently
shown that PLCD1 is a component of the human nail plate by proteomic analysis and is localized in the matrix of human nails. Further-
more, mutations detected in PLCD1 resulted in reduced enzymatic activity in vitro. Our data show that mutations in PLCD1 underlie
hereditary leukonychia, revealing a gene involved in molecular control of nail growth.The nail is a specialized skin appendage with a complex
structure involving a fully keratinized nail plate produced
by the germinative epithelium of the nail matrix. Signifi-
cant advances have been made in the diagnosis and
management of nail diseases, yet our knowledge of the
underlying molecular controls of nail growth and develop-
ment is relatively scant.1 A white appearance of nails can
result from whitening of the nail plate (true leukonychia),
the nail bed (pseudoleukonychia), or neither (apparent
leukonychia) and can be due to a variety of factors
including infectious, metabolic, or systemic diseases,
trauma, or drugs.2 One of the rare causes of whitening of
the nail plate is hereditary leukonychia (MIM 151600), a
rare autosomal-dominant or -recessive nail disorder with
an unknown genetic basis. In hereditary leukonychia,
whitening of the nails may exist as an isolated feature or
be associated with other cutaneous or systemic abnormal-
ities, including keratosis palmoplantaris, pilar and seba-
ceous cysts, severe keratosis pilaris, pili torti, hypotrichosis
with keratoderma, onychorrhexis, koilonychia, renal
calculi, and hair dysplasia with acanthosis-nigricans-like
lesions.2–14
We undertook this study to identify a gene involved in
hereditary leukonychia, with the aim of defining a new
genetic determinant of nail growth in humans. We identi-
fied four families of Pakistani origin showing features of
hereditary leukonychia that were present since birth.
Two of the families included consanguineous marriages
or other features consistent with recessively inherited leu-
konychia (Figure 1C), whereas the other two families
demonstrated dominant inheritance (Figure 1C). All 20
nails of each affected individual were chalky white, consis-
tent with total leukonychia (Figure 1A), although some1Department of Dermatology, Columbia University, New York, NY 10032,
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The Amedisplayed incomplete leukonychia with translucency and
yellowish coloration in the distal parts of the nail plate.
There was a negative family history for malignancy. No
other skin, hair, dermatologic, or systemic findings were
detected. Informed consent was obtained from all subjects
and approval for this study was provided by the Institu-
tional Review Board of Columbia University. The study
was conducted in adherence to the Declaration of Helsinki
Principles. Peripheral blood samples were collected from
members of four Pakistani families as well as 130 unrelated
healthy control individuals of Pakistani origin. Genomic
DNA was isolated from these samples according to stan-
dard techniques.15 We performed a genome-wide scan on
eightmembers of family Awith the low-density Affymetrix
10K SNP array. Genespring GT (Agilent Software) was used
for quality control measures and to perform a number of
analyses. SNPs showing Mendelian inheritance errors
were removed, and the remaining analyzed data set con-
tained 9887 SNPs. Haplotypes, or clusters of SNPs that
tend to be inherited together, were inferred from the data
by Genespring GT. Using haplotypes minimizes the effect
of linkage disequilibrium on multipoint linkage analysis,
reducing type II error. Initial analysis included genome-
wide autozygosity mapping to identify regions identical
by descent that were shared among affected individuals.
We performed parametric linkage analysis twice, once
with SNP genotypes and once with haplotypes. All tests
assumed a recessive mode of inheritance with 100%
penetrance and a disease allele frequency of 0.001. We
identified a region of excess homozygosity shared among
affected individuals on chromosome 3p21.3-p22 (Fig-
ure 1B) with a LOD score (Z) of 5.1. Microsatellite markers
spanning the region of autozygosity were then used toUSA; 2Department of Genetics and Development, Columbia University,
Genetics. All rights reserved.
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Figure 1. Clinical Features of Affected Individuals and Linkage to Chromosome 3 and Identification of Mutations in PLCD1
(A) Complete nail plate leukonychia involving all the finger and toe nails in affected individuals from both recessive families.
(B) Results of autozygosity mapping in family A. The maximum LOD score was obtained for a region on chromosome 3.
(C) Haplotype analysis in families A, B, C, andD. The linked haplotype is indicated in red, and key recombination events are indicated by
arrows.genotype all families, revealing linkage to the same loca-
tion in the other three families (Figure 1C). Key recombina-
tion events were detected between markers D3S1483 and
D3S4134 in the affected individuals V-1 and V-3 of family
A (Figure 1C) and between markers D3S1298 and D3S1260
in the unaffected individual V-6 (Figure 1C), which
allowed the interval of linkage to be narrowed to 2.0 Mb
flanked by markers D3S1483 and D3S1260.
The region of interest harbored 18 known genes, 15
pseudogenes, and 3 predicted transcripts (Figure 2A).
After excluding genes associated with other inherited
disorders and sequencing seven known genes in the
region (STAC [MIM 602317], ITGA9 [MIM 603963],
DCLK3 [MIM 613167], SLC22A13 [MIM 604047], GOLGA4
[MIM 602509], SLC22A14 [MIM 604048], and PLCD1
[MIM 602142] [NM_001130964.1]), we identified pre-
dicted mutations in PLCD1 in all four families (Figures
2B and 2C). All exons of PLCD1 were amplified by PCR
with gene-specific primers (see Table S1 available online).
The PCR products were directly sequenced in an ABI Prism840 The American Journal of Human Genetics 88, 839–844, June 10,310 Automated Sequencer, with the ABI Prism Big Dye
Terminator Cycle Sequencing Ready Reaction Kit (PE
Applied Biosystems). We screened for the PLCD1 muta-
tions in genomic DNA from 130 unrelated healthy control
individuals (260 chromosomes) of Pakistani origin.
Affected individuals of autosomal-recessive family A dis-
played a homozygous mutation c.1309C>T leading to a
premature termination codon p.Arg437X (Figure 2B).
The affected individuals in the second family with auto-
somal-recessive inheritance, family B, also showed a
homozygous protein-truncating mutation consisting of
a 10 bp deletion spanning the splice junction of intron
11 and exon 12 (c.1792-10delTGTAGTGGCC) resulting
in a premature termination codon because of either a
frameshift or missplicing (Figure 2C). By contrast, affected
individuals of families C and D with autosomal-dominant
inheritance displayed heterozygous missense mutations
c.1720C>T (antisense strand) and c.625T>C in PLCD1
leading to the amino acid substitutions p.Ala574Thr and
p.Cys209Arg, respectively (Figures 2D and 2E). None of2011
Figure 2. Identification of Mutations in PLCD1 and Function of Mutant PLCD1
(A) Schematic representation of the candidate region harboring PLCD1. Arrows indicate the position and the direction of transcription
of genes in the region. FCHP, LOC100130503, ARPP21, and STAC are located upstream of the region shown where the axis has been
truncated.
(B and C) Mutation in PLCD1 in families A and B.
(B) Family A; homozygous mutation c.1309C>T, p.Arg437X in an affected individual V-4 (top); heterozygous mutation in an unaffected
carrier V-6 (bottom).
(C) Family B; homozygous mutation c.1792-10delTGTAGTGGCC in affected member V-2 and heterozygous in carrier member V-1 of
family B.
(D) Heterozygous c.1720C>T (antisense strand), p.Ala574Thr in family C.
(E) Heterozygous c.625T>C, p.Cys209Arg in family D.
(F) Function of p.Arg437Xmutant PLCD1 protein in vitro by detection of phospholipase C downstreammetabolite IP1. The quantity of
IP1 was measured by ELISA 48 hr after transfection of HEK293T cells with vector only (negative control), vector and wild-type PLCD1
construct (positive control), and vector and mutant PLCD1 construct. The test was repeated five times and difference was statistically
significant (p < 0.01).the mutations were found in 130 population-matched,
unrelated, unaffected control individuals screened by
restriction enzymes (data not shown) or direct sequencing
(for p.Ala574Thr and p.Cys209Arg, data not shown).
p.Ala574Thr and p.Cys209Arg are both highly conserved
among several organisms (Figure S1A). The identification
of protein-truncating mutations indicated that an absence
or reduction of PLCD1 activity might underlie the leuko-
nychia phenotype in the affected individuals. To confirm
this hypothesis, we assayed the function of the
p.Arg437X mutant PLCD1 in vitro. The wild-type PLCD1-
cDNA was amplified by PCR from human foreskin total
mRNA with the following primers: forward 50-AAACTCG
AGGCCACCATGCAGTGCCTGGGGATC-30 and reverse
50-AAAGGTACCGGCCTAGTCCTGGAGGGAGATC-30. The
PCR product was cloned into the mammalian expression
vector pCXN2.116 with XhoI and KpnI sites. The expres-
sion construct for the p.Arg437X mutant PLCD1-
p.Arg437X-pCXN2.1 was generated with the QuikChange
II XL Site-Directed Mutagenesis Kit (QIAGEN) with theThe AmePLCD1-pCXN2.1 construct as a template. To measure
PLCD1 function, accumulation of its downstreammetabo-
lite, inositol monophosphate (IP1), was quantified with
IP-One ELISA competitive immunoassay kit (Cisbio). We
plated 1.5 3 105 HEK293 cells on 24-well plates and
transfected with pCXN2.1 (vector only), the wild-type
PLCD1 containing construct (PLCD1-pCXN2.1), or the
mutant (p.Arg437X) PLCD1 containing construct (PLCD1
p.Arg437X-pCXN2.1) with Fugene transfection reagent
(Invitrogen). Forty-eight hours after transfection, cells
were stimulated in the presence of LiCl causing the
accumulation of IP1 upon receptor activation and cell
lysates were collected. Competitive immunoassay with
IP1-HRP and a IP1 monoclonal antibody was then carried
out according to manufacturer’s instructions. The optical
density (OD) was read at 450 nm with BioRad microplate
reader model 680.
We founda significant reduction (p<0.01) in IP1, adown-
stream metabolite of inositol 1,4,5-trisphosphate (IP3) that
accumulates in cells after activation of phospholipaserican Journal of Human Genetics 88, 839–844, June 10, 2011 841
Figure 3. PLCD1 Localization in Human Embryo Nail
(A–C) Anatomy of human embryo nail by (A) hematoxylin and eosin staining (M, nail matrix; B, nail bed) and by (B and C) PLCD1 stain-
ing (purple indicates positive staining) revealing cytoplasmic and membranous localization of PLCD1.
(D) Negative control.C-coupled receptors, PLCD1 in 293 cells transfected with
the mutant construct compared with the wild-type
(Figure 2F).
To further implicate PLCD1 in the pathogenesis of
hereditary leukonychia, we examined its localization in
the nail. For PLCD1 immunohistochemistry, paraffin-
embedded sections of human fetal (IRB-AAAB2447) nail
were used. Antigen unmasking was carried out with
Antigen Unmasking Solution (Vector Laboratories). After
blocking with normal goat serum, samples were incubated
with a rabbit polyclonal antibody raised against human
PLCD1 (1:50 dilution; HPA020107; Sigma Prestige) at 4C
overnight in a humidified chamber. Primary antibody
was omitted from the negative control. To visualize the
staining, the Vectastain Elite rabbit ABC-AP kit (Vector
Laboratories) and alkaline phosphatase (AP) staining with
5-Bromo-4-chloro-3-indolyl phosphate and 4-Nitro Blue
Tetrazolium Chloride (Roche Applied Science) in AP stain-
ing buffer (100 mM Tris [pH 9.5], 50 mM MgCl2, 10 mM
NaCl, and 1% Tween 20 in H2O) were used. By immuno-
histochemistry analysis, prominent localization was
detected in the nail matrix and the nail bed (Figures 3A–
3D).We then isolated total RNA from plucked human scalp
hair, human scalp, human foreskin, and foreskin-derived
keratinocytes and fibroblasts with the RNeasy Minikit
(QIAGEN). 2 mg of total RNA was reverse transcribed with
random primers and SuperScript III (Invitrogen). The
cDNAs were then amplified by PCR with PLCD1-specific
primers (forward 50-CAGCGTCAGAAGCTACAGCA-30,842 The American Journal of Human Genetics 88, 839–844, June 10,reverse 50-TCTGTCTGGGAGTGGTCACA-30) and SYBR
Green master mix. The PCR reactions were run in an
Applied Biosystems Sequence Detection System 7700.
Relative expression levels were calculated with the DDCt
method (Applied Biosystems), with GAPDH as the internal
control. The expression level of human scalp was set as the
calibrator. Although PLCD1 mRNA was expressed in
human skin and hair follicle as evidenced by real-time
quantitative RT-PCR analysis (Figure S1B), we found no
evidence of hair or skin abnormalities in the affected indi-
viduals.
Although many hereditary disorders with isolated or
combined nail defects have been described, the underlying
gene defect in most of these diseases is yet unknown.1
Some of the genes implicated in human nail diseases
include LMX1B (MIM 602575), a transcription factor that
regulates collagen IV expression in the nail-patella
syndrome (NPS [MIM 161200]),17 K6 (MIM 148041), K16
(MIM 148067), and K17 (MIM 148069) in pachyonychia
congenita type 1 (PC1 [MIM 167200]) and pachyonychia
congenita type 2 (PC2 [MIM 167210]), a group of rare auto-
somal-dominant ectodermal dysplasias,18 and RSPO4
(MIM 610573), a Wnt signaling ligand we found to be
mutated in congenital anonychia (MIM 206800).19 Previ-
ously, Norgett et al.20 showed genetic linkage in a family
with autosomal-dominant hereditary leukonychia to the
type II cytokeratin locus on 12q13 and detected abundant
intracellular vacuoles and a lesser compactness of keratins
in the affected nails, postulating that the white appearance2011



























not testedof nails seemed to be due to an abnormal keratinization of
cells originating from the proximal nail matrix.
The finding of PLCD1 mutations in four families with
autosomal-recessive and autosomal-dominant hereditary
leukonychia (Table 1) broaden our knowledge of genetic
control of nail growth in humans and emphasize the
involvement of nonkeratin genes in these processes.
Phosphoinositide-specific phospholipase C (PLC) is a
key enzyme in phosphoinositide turnover by hydrolyzing
phosphatidylinositol 4,5-bisphosphate (PIP2) to generate
two second messengers, diacylglycerol (DG) and IP3.20
DG further mediates the activation of protein kinase C,
and IP3 releases calcium from intracellular stores playing
a role in a variety of physiological functions.21 PLCs are
divided into six isotypes: four b, two g, four d, one 3,
one z, and one h types. The catalytic domains of all
PLCs share 40%–60% similarity. These isotypes are regu-
lated by different mechanisms. For instance, PLC-b isoen-
zymes are activated by the Gaq/11 family of heterotri-
meric G-proteins and bg subunits are released from the
Gai/o family while PLC-g isoenzymes are activated by
tyrosine kinases through tyrosine phosphorylation. PLC-
3 is activated by Ga12 and ras through membrane translo-
cation. These isotypes are expressed in various tissues
where they are believed to play fundamental roles in trig-
gering cellular responses.22 Recently, it was found that
PLCD1 acts as a tumor-suppressor gene in cell lines of
gastric and breast cancer.23,24 None of our families in
this study reported any history of malignancies.
Interestingly, Plcd1-deficient mice undergo progressive
hair loss because of epidermal hyperplasia, occlusion of
the hair canal, sebaceous gland hyperplasia, and formation
of abnormal cysts, though a nail phenotype was not
described.25 Furthermore, Plcd1-knockout mice share
striking phenotypic similarity to the Foxn1-deficient
nude mice, whose skin defects are caused in part by insuf-
ficient expression of Plcd1.26 Further studies are needed to
examine the link between Plcd1 and the nail dystrophy in
nude mice. Nude mice also have nail dystrophy with
shorter and abnormally shaped nails, severe parakeratosis
of the dorsal nail plate because of dysplasia and impairedThe Amecornification of the nail matrix, and lower nail plate sulfur
concentrations.27 Although PLCD1 mRNA was expressed
in human skin and hair follicle as shown by real-time
quantitative RT-PCR analysis, we found no evidence of
hair or skin abnormalities in the affected individuals,
suggesting that other members of the phosphoinositide-
specific phospholipase C family may compensate for the
PLCD1 defect in the skin and the hair follicle.
Most recently, it was shown through proteomic studies
that PLCD1 is abundant in human nails.28 Themechanism
through which it leads to the formation of leukonychia
remains to be determined. The phenomenon that recessive
and dominant mutations in the same gene result in a
similar phenotype is very rare. Ataxia telangiectasia (AT
[MIM 208900]) is an autosomal-recessive condition caused
by mutations in ATM (MIM 607585). In 2008, Smirnov
and Cheung investigated the effect of heterozygous and
homozygous ATM mutations on gene and microRNA
expression and found that some genes and/or pathways
require only one wild copy of ATM to function normally
whereas others require two copies. In summary, they
demonstrated that mutations in ATM result in both
recessive and dominant expression phenotypes of genes
and microRNAs. Moreover, recessive and dominant muta-
tions in keratins 5 and 14 have been reported in epidermol-
ysis bullosa simplex (EBS).29,30 This is one possibility that
can explain the occurrence of white nails in the setting
of recessive or dominant mutations. A second possibility
would be that the missense mutations exert a dominant-
negative effect on the wild-type allele with complete loss
of function.31
In conclusion, our findings indicate that mutations in
PLCD1 underlie hereditary leukonychia and, more
broadly, reveal a gene involved in controlling nail growth
in humans.
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